Senile dementia recombinant adenovirus gene vaccine and preparation method thereof

Abstract

The invention discloses senile dementia Ad-GFP gene vaccine and a preparation method theerof and is Ad-GFP vaccine of flexible foldable multivalence Beta- amyloid 1-15 (ABeta1-15) of secretion co-expression and genetic adjuvant, which a flexible connecting peptide is used for connecting multivalence. The invention selects foldable multivalence ABeta1-15 as immunogen, which avoids the space rigid structure of multiple copy ABetaB cell epitopes, also ensures that ABeta15 epitopes are more easily exposed, thus enhancing immunogenicity and also increasing immunogenic molecular weight and reducing the possibility of degradation; a antigen delivery system that takes adenovirus as a carrier is selected, which avoids the defects of high challenge and high cost of chemosynthesis.

Description

technical field [0001] The invention relates to a vaccine and a preparation method thereof, in particular to a recombinant multivalent β-amyloid 1-15 (Aβ) for senile dementia 1-15 ) adenovirus vaccine and its preparation method. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized clinically by progressive memory and loss of acquired knowledge until the patient loses the ability to live. With the increase of the number of cases, AD brings a heavy burden to the family and society, and is an important social and medical health problem. Regarding the treatment of AD, there is no ideal method at present. The existing treatment strategies mainly focus on relieving symptoms, but do not prevent the pathological process of AD, and their clinical efficacy is not satisfactory. Aβ is the main component of senile plaques in the pathological changes of senile dementia, which consists of 39-42 amino acids. Recent studies have shown that th...

AI Technical Summary

Problems solved by technology

[0003] There are still many unsatisfactory aspects of the second-generation AD vaccines reported in recent literature: 1) Most of the antigens prepared by researchers are chemically synthesized, and the chemical modification of synthetic peptides is difficult, costly, and not high in purity

2) When researchers prepare multivalent vaccines containing Aβ N-terminal B-cell epitopes, most of them connect the B-cell epitope fragment directly with a new T-cell epitope, or directly connect the B-cell epitope in series, It is easy to affect the spatial structure of the antigen, which is not conducive to the exposure of the B cell epitope of Aβ

Images